I don't doubt he (or something else) is causing a share price increase after frankly a very bad quarterly result. Still if the company manages to submit (and get the file accepted) the stock could be in line for a major move on potential FDA approval. To me its more riskier the company properly completes the file and is accepted. They should get priority review and then we're looking at a Q3 potential approval. Even if they aren't ready to launch (which unfortunately I think mangement likely won't be) the stock should be significantly higher. Lets just hope they stop the uniform pricing nonsense for the US.
I really wish they would have some experienced/competent people moving it forward if not its probably more value creation if someone comes and buys us out who knows what they're doing in rare diseases.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM